{"article_title": "The Coming Perfect Storm In Medical Innovation: Can FDA Be A Life-Boat ?", "article_keywords": ["perfect", "fda", "lifeboat", "medical", "innovation", "storm", "coming"], "article_url": "http://www.forbes.com/sites/tomasphilipson/2014/03/05/the-coming-perfect-storm-in-medical-innovation-can-fda-be-a-life-boat/", "article_text": "", "article_metadata": {"description": "Looming cuts in both NIH-funding and provider reimbursements is a perfect storm that will hit academic medical research centers hard. However, licensing revenues, which come from selling discoveries made in these academic centers to those that develop valuable new treatments, can provide additional revenue. The problem is that current FDA policies dramatically lower the price at which academic centers can sell their discoveries.", "author": "Tomas Philipson", "og": {"site_name": "Forbes", "description": "Looming cuts in both NIH-funding and provider reimbursements is a perfect storm that will hit academic medical research centers hard. However, licensing revenues, which come from selling discoveries made in these academic centers to those that develop valuable new treatments, can provide additional revenue. The problem is that current FDA policies dramatically lower the price at which academic centers can sell their discoveries.", "title": "The Coming Perfect Storm In Medical Innovation: Can FDA Be A Life-Boat ?", "url": "http://www.forbes.com/sites/tomasphilipson/2014/03/05/the-coming-perfect-storm-in-medical-innovation-can-fda-be-a-life-boat/", "image": "http://blogs-images.forbes.com/tomasphilipson/files/2014/03/8100980391_92a2e64e86_b.jpg", "updated_time": "2014-03-05T13:05:49-05:00", "type": "article"}, "twitter": {"site": "@forbes", "image": "http://blogs-images.forbes.com/tomasphilipson/files/2014/03/8100980391_92a2e64e86_b.jpg", "description": "Looming cuts in both NIH-funding and provider reimbursements is a perfect storm that will hit academic medical research centers hard. However, licensing revenues, which come from selling discoveries made in these academic centers to those that develop valuable new treatments, can provide additional revenue. The problem is that current FDA policies dramatically lower the price at which academic centers can sell their discoveries.", "card": "summary_large_image", "title": "The Coming Perfect Storm In Medical Innovation: Can FDA Be A Life-Boat ?"}, "apple-itunes-app": "app-id=588647136", "fb": {"app_id": 123694841080850}, "keywords": "OpEd,Policy,Politics,regulation,Op/Ed,Andrew von Eschenbach,economics,FDA,Food and Drug Administration,health,innovation,intellectual property,medicine,National Institutes of Health,NIH,pharmaceuticals,reimbursement,research,Tomas J. Philipson", "article": {"publisher": "https://www.facebook.com/forbes", "section_url": "http://www.forbes.com/opinion", "section": "Opinion", "modified": "2014-03-05", "published": "2014-03-05", "id": "blogAndPostId/blog/post/2838-196"}, "news_keywords": "OpEd,Policy,Politics,regulation,Op/Ed,Andrew von Eschenbach,economics,FDA,Food and Drug Administration,health,innovation,intellectual property,medicine,National Institutes of Health,NIH,pharmaceuticals,reimbursement,research,Tomas J. Philipson", "viewport": "width=device-width,initial-scale=1,maximum-scale=1,user-scalable=no", "prerender-status-code": "{{meta.code}}"}, "_id": "\"57477af46914bd0286fd8227\"", "article_summary": ""}